Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma

Prognosis in children with refractory and relapsed high-risk neuroblastoma is poor. Only a minority of patients obtain remission when treated with second-line chemotherapy regimens. Chemotherapy combined with anti-GD2 antibodies has previously been shown to increase response and survival rates. We r...

Descripción completa

Detalles Bibliográficos
Autores principales: Wieczorek, Aleksandra, Zaniewska-Tekieli, Anna, Ehlert, Karoline, Pawinska-Wasikowska, Katarzyna, Balwierz, Walentyna, Lode, Holger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936065/
https://www.ncbi.nlm.nih.gov/pubmed/36816982
http://dx.doi.org/10.3389/fonc.2023.1082771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936065/
https://www.ncbi.nlm.nih.gov/pubmed/36816982
http://dx.doi.org/10.3389/fonc.2023.1082771

Ejemplares similares